Elucid
Boston
About Elucid
Based in the Boston biotech and medtech hub, Elucid is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $166.2M
- Funding stage: Late Stage Venture
- Last round: Series D (Oct 2025)
- Website: elucid.com
- Phone: 617-329-9487
Industries & Categories
Analytics, Biotechnology, Medical Device, Precision Medicine
Social Profiles
Canonical: https://fsome.com/organization/elucid-19249 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.